| Name | Title | Contact Details |
|---|
Get hassle-free reproductive care for Herpes, BV, Yeast, UTI, Primary Care & Contraception. Same-day prescriptions picked up locally in a few hours or delivered FREE, discreetly packaged, to your home.
At Shannondale, we believe our residents` senior years should be stress-free and wonderful, so we offer a full continuum of care from short-term rehab to independent living to assisted or skilled nursing. We offer two locations in Knoxville and Maryville. Our community at Shannondale is strengthened by nurturing, compassionate, experienced staff who have innate passion for caring for others. We pride ourselves in a welcoming environment not only for residents, but for staff as well, with competitive benefits.
We are dedicated to quality service for the medically fragile child. We service our patients based on each child's specific needs to develop their potential through clinical education and technical support. We believe it takes more than health care to
Nodality is an innovative personalized medicine company focused on improving the efficiency of drug development for therapeutics as well as generating highly predictive companion diagnostics to improve patient care.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.